Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen
Wieneke A
WA
Burgers
Jacobus A
JA
Vincent
Andrew D
AD
Schellens
Jan H M
JH
Beijnen
Jos H
JH
Smit
Egbert F
EF
Joerger
Markus
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D015972:Gene Expression Regulation, Neoplastic; D005820:Genetic Testing; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D018579:Patient Selection; D000068437:Pemetrexed; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine